Watchlist Price Alert

BioNTech SE (BNTX)

NASDAQ: BNTX · Real-Time Price · USD

107.00

-0.51 (-0.47%)

At close: Jul 02, 2025, 10:13 AM

-0.47% (1D)

Bid	77.04
Market Cap	25.72B
Revenue (ttm)	2.75B
Net Income (ttm)	-768.64M
EPS (ttm)	-3.66
PE Ratio (ttm)	-29.23
Forward PE	-18.86
Analyst	Buy

Ask	136.14
Volume	154,446
Avg. Volume (20D)	1,181,391
Open	107.09
Previous Close	107.51
Day's Range	106.10 - 107.52
52-Week Range	76.53 - 131.49
Beta	1.28

About BNTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BNTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BNTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

BioNTech SE is scheduled to release its earnings on Aug 4, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 weeks ago

+18.05%

BioNTech shares are trading higher after the compa... Unlock content with Pro Subscription

1 month ago

+4.01%

Shares of vaccine stocks are trading higher following a report indicating FDA advisers will consider if COVID-19 vaccines should target the LP.8.1 subvariant for 2025-2026.

News

2 weeks ago · schaeffersresearch.com

CureVac Stock Soars on BioNTech Buyout

Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.

2 weeks ago · benzinga.com

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.

2 weeks ago · proactiveinvestors.com

BioNTech boosts cancer mRNA pipeline with CureVac acquisition

BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, e...

2 weeks ago · barrons.com

BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

CureVac stock soared 29% $5.26 in premarket trading immediately following the news.

2 weeks ago · reuters.com

BioNTech to acquire CureVac in $1.25 billion all-stock deal

German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.

3 weeks ago · cnbc.com

RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say

Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trus...

3 weeks ago · reuters.com

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccin...

3 weeks ago · barrons.com

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.

3 weeks ago · investors.com

Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.

Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.

3 weeks ago · seekingalpha.com

Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment

Bristol-Myers Squibb is attractively valued, offers a 5%+ dividend yield, and benefits from a strong oncology pipeline after its BioNTech deal. The $11B BioNTech partnership gives BMY access to BNT327...

Load More News